UBS raised the firm’s price target on CVS Health (CVS) to $100 from $97 and keeps a Buy rating on the shares. CVS delivered a strong Q1 beat with improved margins, raised guidance, and confidence in its PBM and healthcare benefits outlook, while management reinforced that FY26 targets and mid-teens EPS growth remain intact despite near-term volatility from utilization trends, seasonality, and policy noise, with longer-term upside tied to clearer visibility on Medicare Advantage margins and capital return, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health reports Q1 adjusted EPS $2.57, consensus $2.21
- CVS Health raises FY26 adjusted EPS view to $7.30-$7.50 from $7.00-$7.20
- CVS Health raises FY26 revenue view to ‘at least’ $405B from ‘at least’ $400B
- CVS Health says ‘encouraged’ by Q1 performance
- CVS Health says confident in adequacy of reserves